Author |
Study type |
N |
Chemotherapy |
RE |
Disease Control* (%) |
Median PFS
(months) |
Toxicity** (%) |
Van Hazel |
Dose escalation |
25 |
Irinotecan
(50-100 mg/m2) |
Whole liver |
87 |
6.0 |
28 |
Lim |
Prospective registry |
30 |
Bolus 5-FU |
Whole liver |
60 |
5.3 |
23 |
Hendlisz |
Phase III |
23
23 |
5-FU
(225-300 mg/m2)
5-FU (300 mg/m2) |
Whole liver
N/A |
86
35 |
4.5
2.1 |
4
26 |
Chua |
Case series |
140 |
5-FU 225 mg/m2 |
Involved lobe(s) |
63 |
NR |
NR |
Cohen |
Dose escalation |
21 |
Capecitabine (375-1000 mg/m2) |
Lobar |
95 |
NR* |
17 |
*Defined as sum of percentage of patients with complete response, partial response, or stable disease
**Defined as either grade 3/4 or serious non-hematological toxicity |